Close Menu

NEW YORK (360Dx) – French diagnostic and theranostics firm Theradiag today said it has raised more than €4 million ($4.4 million) after issuing shares to "a specific category of persons."

Theradiag sold 1.7 million new shares at €2.30 per share. The shares were issued following an accelerated bookbuilding process, the firm said, adding the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.